SLDB (Solid Biosciences) Short Interest


SLDB Solid Biosciences Inc SLDB
34 GF Score
Price $10.84
! 2 Warning Signs
View Full Analysis

What is Solid Biosciences Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

SLDB vs JANX, MRVI, TBPH: Short Interest Comparison

For the Biotechnology subindustry, Solid Biosciences's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Solid Biosciences Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Solid Biosciences's Short Interest distribution charts can be found below:

* The bar in red indicates where Solid Biosciences's Short Interest falls into.


SLDB
34GF Score
Solid Biosciences Inc SLDB
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Solid Biosciences Business Description

Address 500 Rutherford Avenue, Third Floor, Charlestown, MA, USA, 02129
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
34GF Score

Get the complete analysis for SLDB

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.84
Price